Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $870,676 | $591,893 | $665,568 | $606,941 |
| - Cash | $22,408 | $37,412 | $37,076 | $36,330 |
| + Debt | $922 | $4,999 | $1,189 | $1,289 |
| Enterprise Value | $849,190 | $559,480 | $629,681 | $571,900 |
| Revenue | $529 | $10,739 | $1,764 | $1,574 |
| % Growth | -95.1% | 508.8% | 12.1% | – |
| Gross Profit | $518 | $10,739 | -$7,195 | -$7,236 |
| % Margin | 97.9% | 100% | -407.9% | -459.7% |
| EBITDA | -$7,708 | $2,562 | -$24,165 | -$15,335 |
| % Margin | -1,457.1% | 23.9% | -1,369.9% | -974.3% |
| Net Income | -$7,742 | $2,523 | -$24,526 | -$12,532 |
| % Margin | -1,463.5% | 23.5% | -1,390.4% | -796.2% |
| EPS Diluted | -0.04 | 0.013 | -0.13 | -0.068 |
| % Growth | -405.3% | 110.1% | -92.6% | – |
| Operating Cash Flow | -$5,817 | -$15,749 | -$13,391 | -$10,315 |
| Capital Expenditures | $0 | $0 | $0 | -$86 |
| Free Cash Flow | -$5,817 | -$15,749 | -$13,391 | -$10,401 |